- Home
- TRDA
as 05-30-2025 4:00pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 336.6M | IPO Year: | 2021 |
| Target Price: | $25.67 | AVG Volume (30 days): | 144.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.61 | EPS Growth: | -13.89 |
| 52 Week Low/High: | $7.10 - $21.79 | Next Earning Date: | 05-08-2025 |
| Revenue: | $172,220,000 | Revenue Growth: | 5.74% |
| Revenue Growth (this year): | -80.79% | Revenue Growth (next year): | -23.26% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Mar 17 '25 | Sell | $10.67 | 1,784 | $19,035.28 | 109,536 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
3 days ago
Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
GlobeNewswire
4 days ago
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Simply Wall St.
21 days ago
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
Zacks
24 days ago
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
24 days ago
Entrada Therapeutics Reports First Quarter 2025 Financial Results
Zacks
a month ago
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
BioPharma Dive
a month ago
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda
Zacks
a month ago
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.